Sep 2026· Trends in Biotechnology· 0 citations· 84 references
Medicine
TL;DR
A multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics are introduced to enhance minimal residual disease detection and guide precision neuro-oncology.
Abstract
Glioblastoma remains highly aggressive, with limited treatment response and poor prognosis. Tissue biopsy (TB) is invasive and fail to capture tumor heterogeneity or temporal dynamics. Liquid biopsy (LB) provides a noninvasive alternative for real-time monitoring via circulating biomarkers, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in plasma, cerebrospinal fluid (CSF), urine, and saliva. This review advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability. We introduce a multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection and guide precision neuro-oncology.
Liquid biopsy represents a promising complementary approach to conventional tissue pathology and neuroimaging in glioblastoma and its greatest future value may lie in longitudinal molecular monitoring and integration with MRI, radiomics, artificial intelligence, and other molecular profiling approaches.
Usha Topalkatti, Jhansi Mani Mahadeva· International Journal of Inn...· 0 citations
: Liquid biopsy has emerged as a revolutionary, minimally invasive approach in precision oncology, enabling dynamic molecular profiling of tumors through analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers in body fluids. Focusing specifically on recent advances fro...
Ya-Qiong Guo, Xue-Ling Wei, Lin Zhu et al.· OncoTargets and Therapy· 0 citations
This narrative review comprehensively summarizes the current evidence linking these four liquid biopsy analyte categories to MVI in HCC, evaluates their integration into multi-omics predictive models, and proposes an evidence-level framework that categorizes blood biomarkers according to the strength of their support f...
The feasibility of integrating multimodal liquid biopsy and volumetric imaging into routine neurosurgical practice for GBM is demonstrated, and the proposed workflow provides a reproducible foundation for larger studies aimed at advancing clinical implementation of liquid biopsy strategies.
M. Chiapponi, Fabiola Cappella, Laura Andreacchio et al.· Neuro-Oncology Practice· 0 citations
Glioblastoma and diffuse gliomas pose major therapeutic challenges due to marked intratumoral heterogeneity, limited tissue accessibility, and the blood–brain barrier. Tissue-based next-generation sequencing (NGS) remains essential for WHO CNS5 molecular classification, yet it is invasive and poorly suited to serial mo...
K. Kubiak, Edyta Szurowska· International Journal of Mol...· 0 citations
Liquid biopsy has emerged as an important minimally invasive technology in contemporary oncology, enabling repeated assessment of tumor-derived molecular information through blood and other biological fluids. Circulating tumor DNA (ctDNA), circulating tumor cells, cell-free DNA methylation patterns, extracellular vesic...
Vanessa Gąsiorowska, Karolina Grodkowska-Szukała, Ewa Jachimczak et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
